Incubation in vitro of natural (ovine) or synthetic TRF (PCA-His-Pro-NH2) with rat blood, plasma, or reconstituted lyophilized serum destroys the biological activity. Inactivation of TRF by normal plasma takes place at 0 °C but at a slower rate than at 37 °C. Plasma obtained from rats several weeks after hypophysectomy and/ or hypophysectomy + thyroidectomy inactivates TRF. TRF activity is not recovered from TRF incubated in plasma when the incubate is treated with NaCl (4 m), ethanol (80% v/v) or HCl (to pH 1). Plasma inactivation of TRF is completely prevented by pretreatment of the plasma with ethanol (80% v/v); heating of plasma at 65 °C for 15 min also destroys the ability of plasma to inactivate TRF. The data reported are consistent with the hypothesis that plasma contains an enzyme (s) which destroys the activity of TRF. Plasma was also found to destroy the biological activity of PCA-His-Pro-OMe and PCA-His-Pro-OH (2 synthetic tripeptides with TRF activity). The biological activity of PCA-His-Pro-OH is destroyed in vitro at a slower rate by plasma than that of PCA-His-Pro-NH2 or natural TRF. Addition of the dipeptide analogue of TRF, PCA-His-OMe, prevents in vitro the inactivation of TRF by plasma.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.